
Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease that increases with age. Because of this, and due to its chronic complications, T2DM causes high human, social, and financial costs. In addition, the elderly population with T2DM has a marked clinical heterogeneity. Therefore, our main objective was to analyze the relationship of age with the clinical and biological manifestations of the disease and the prevalence of chronic complications in patients with T2DM.
The aim of this study was to detect people at risk of suffering diabetes or changes in carbohydrate metabolism and to refer them for possible diagnosis to health care centers. The number of diagnoses and costs for the pharmacy were recorded. A cross-sectional, observational study was conducted in community pharmacies in Pontevedra in September–October of 2014. The Findrisc questionnaire was completed by pharmacy users over 18 years old. If Findrisc score was ≥15, capillary blood glucose was measured, and the participant was referred to a physician if the value was ≥110 mg/dL. The main variables included score in the Findrisc questionnaire, number of diabetes diagnosed, and cost of the service. Differences between the groups were calculated using a Chi-squared test, a Student's t test, and/or a Wilcoxon test. This study was conducted in 180 pharmacies on a sample of 4222 users, including 992 (23.5%) with a high or very high risk of diabetes (F ≥ 15). In the 1060 basal capillary blood glucose tests performed, mean glucose level was 110.2 (SD = 20.4) mg/dL (56–254). The Galician Health Service sent information about 83 of the 384 (9.1%) subjects referred to a physician: 28 (33.7%) of them were diagnosed with diabetes (3.1% of the sample), and 26 (31.3%) were diagnosed with prediabetes (2.8% of the sample). Cost per diagnosed subject was €184.22 per subject with diabetes and €96.86 per subject with prediabetes. The proportion of subjects with new diagnosis of diabetes (3.1%) shows the high efficiency of a screening program for hidden diabetics implemented at community pharmacies as the one presented here. Pilotar una actividad profesional consistente en la detección de personas en riesgo de padecer diabetes o alteraciones del metabolismo de los hidratos de carbono y derivación para posible diagnóstico en los centros de salud. Comprobación del número de diagnósticos y evaluación del coste para la farmacia. Estudio observacional transversal en farmacias comunitarias de Pontevedra en septiembre-octubre de 2014. Cuestionario Findrisc a usuarios de la farmacia con más de 18 años. Con Findrisc ≥ 15 determinación de la glucemia basal capilar y derivación al médico con ≥110 mg/dL. Variables principales: puntos en cuestionario Findrisc, número de diagnósticos de diabetes, coste del servicio. Las diferencias entre grupos se calcularon con el test de chi-cuadrado, t de Student o test de Wilcoxon. El estudio se realizó en 180 farmacias. La muestra incluyó a 4.222 usuarios. De ellos, 992 (23,5%) tenían alto o muy alto riesgo de diabetes (F ≥ 15). Se realizaron 1.060 test de glucemia basal capilar, con un resultado medio de 110,2 (DE = 20,4) mg/dL (56-254). De los 384 (9,1%) sujetos derivados al médico, el Servicio Gallego de Salud envió información de 83: 28 (33,7%) diagnosticados de diabetes (3,1% de la muestra) y 26 (31,3%) de prediabetes (2,8%). El coste por sujeto diagnosticado fue de 184,22 € y por sujeto con diabetes o prediabetes fue de 96,86 €. El número de diagnósticos de nuevos pacientes diabéticos, 3,1% de la muestra total, muestra la alta eficiencia de un programa de cribado para diabéticos ocultos realizado en farmacias comunitarias como el que aquí se presenta.
Introduction: To analyze the efficacy and safety of empagliflozin combined with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.Methods: Pooled analysis of three phase III trials in patients with type 2 diabetes mellitus (n = 1,801) who received placebo or empagliflozin 10 or 25 mg once daily for 24 weeks, in combination with metformin, metformin + sulphonylurea or pioglitazone +/- metformin.Results: Empagliflozin significantly decreased HbA1c (adjusted mean reduction vs placebo with empagliflozin 10 mg: -0.58% [95% CI: -0.66; -0.49]; P<.0001, and with empagliflozin 25 mg:- 0.62% [95% CI: -0.70; -0.53], P<.0001), weight (adjusted mean reduction vs placebo with empagliflozin 10 mg: -1.77 kg [95% CI: -2.05; -1.48]; P<.0001, and with empagliflozin 25 mg: -1.96 kg [95% CI: -2.24; -1.67], P<.0001), and systolic and diastolic blood pressure (SBP/DBP). Adverse effect rates were 64% with placebo, 63.9% with empagliflozin 10 mg, and 60.9% with empagliflozin 25 mg. Documented episodes of hypoglycemia (<= 70 mg/dL and/or requiring care) occurred in 3.9% of patients with placebo, 6.9% of patients with empagliflozin 10 mg, and 5.3% of patients with empagliflozin 25 mg. Urinary tract infections developed in 9.4% of patients with placebo, 10.2% of patients with empagliflozin 10 ring, and 8.3% of patients with empagliflozin 25 mg. Genital infections were reported in 1.0% of patients with placebo, 4.6% of patients with empagliflozin 10 mg, and 3.5% of patients with empagliflozin 25 mg.Conclusions: Empagliflozin combined with other oral treatments decreased HbA1c, body weight, and SBP/DBP as compared to placebo, with a good safety and tolerability profile. (C) 2016 SEEN. Published by Elsevier Espana, S.L.U. All rights reserved.
The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein (LDL) receptor (LDLR) and directs it to the lysosome for degradation. This results in decreased numbers of LDLR available on the cell surface to bind LDL particles and remove them from the circulation and a subsequent increase in circulating LDL-cholesterol (LDL-C) concentrations. Since the role PCSK9 plays in LDL-C metabolism has been discovered in 2003, there have been major efforts in finding efficient and safe methods to inhibit it. Amongst those, the PCSK9 antibodies are the furthest in development, with multiple phase III and cardiovascular endpoint trials already underway. These fully human monoclonal antibodies have been extensively studied in a wide range of subjects such as in those with statin intolerance, as add-on to statin therapy, as monotherapy and in patients with familial hypercholesterolemia. PCSK9 antibodies have shown to be associated with a consistent robust additional decrease in LDL-C concentrations of around 50–70%. If the safety data from the ongoing phase III trials remain as reassuring as the data available till now, PCSK9 antibodies are going to offer a new, powerful therapeutic option to decrease LDL-C concentrations and hopefully cardiovascular risk.
El tratamiento convencional de la obesidad con dieta y ejercicio así como la cirugía bariátrica tienen sus limitaciones, por lo que es necesario disponer de fármacos para su tratamiento. En el pasado se comercializaron diferentes fármacos que fueron retirados por problemas de seguridad. Actualmente existen 3 fármacos aprobados por la Agencia Europea del Medicamento (EMA) y la Food and Drug Administration (FDA) para el tratamiento de la obesidad (orlistat, combinación de bupropión y naltrexona de liberación retardada y liraglutida) y 2 más solo autorizados por la FDA (lorcaserina y la combinación de fentermina y topiramato de liberación prolongada). Se aconseja su uso como segunda línea terapéutica y su elección debe individualizarse teniendo en cuenta múltiples aspectos como la pérdida de peso esperada, la vía de administración, su perfil de seguridad y el coste. Por otra parte, actualmente existen varios fármacos en vías de desarrollo que actúan sobre diferentes dianas terapéuticas.Conventional treatment for obesity with diet, exercise and bariatric surgery has limitations; thus, it is necessary to have pharmacological tools. In the past, different drugs were marketed that were withdrawn due to safety problems. There are currently 3 drugs approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for obesity therapy (orlistat, combination of bupropion and delayed-release naltrexone and liraglutide) and two more only authorized by FDA (lorcaserin and the combination of phentermine and extended release topiramate). It is recommended to use as a second therapeutic line and its choice should be individualized taking into account multiple aspects such as expected weight loss, route of administration, safety profile and cost. Currently there are several drugs under development that act on different therapeutic targets.